Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001683168-25-003701
Filing Date
2025-05-15
Accepted
2025-05-15 16:06:03
Documents
61
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q FOR MAR 2025 sunshine_i10q-033125.htm   iXBRL 10-Q 550307
2 CERTIFICATION sunshine_ex3101.htm EX-31.1 11151
3 CERTIFICATION sunshine_ex3102.htm EX-31.2 11136
4 CERTIFICATION sunshine_ex3201.htm EX-32.1 4374
10 GRAPHIC logo.jpg GRAPHIC 6215
  Complete submission text file 0001683168-25-003701.txt   3638179

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE sbfm-20250331.xsd EX-101.SCH 32027
6 XBRL CALCULATION FILE sbfm-20250331_cal.xml EX-101.CAL 47588
7 XBRL DEFINITION FILE sbfm-20250331_def.xml EX-101.DEF 145771
8 XBRL LABEL FILE sbfm-20250331_lab.xml EX-101.LAB 238581
9 XBRL PRESENTATION FILE sbfm-20250331_pre.xml EX-101.PRE 206970
63 EXTRACTED XBRL INSTANCE DOCUMENT sunshine_i10q-033125_htm.xml XML 417529
Mailing Address 333 LAS OLAS WAY CU4 SUITE 433 FORT LAUDERDALE FL 33301
Business Address 333 LAS OLAS WAY CU4 SUITE 433 FORT LAUDERDALE FL 33301 954-515-0810
Sunshine Biopharma Inc. (Filer) CIK: 0001402328 (see all company filings)

EIN.: 205566275 | State of Incorp.: CO | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41282 | Film No.: 25952751
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)